venetoclax + azacitidine + cedarbenazine + dexamethasone

This is a combination regimen consisting of four drugs: - **Venetoclax** is a small molecule BCL-2 inhibitor that promotes apoptosis in cancer cells, particularly used in hematologic malignancies such as acute myeloid leukemia (AML). - **Azacitidine** is a hypomethylating agent that incorporates into DNA and RNA, leading to DNA hypomethylation and cytotoxicity, primarily used for myelodysplastic syndromes and AML. - **Cedarbenazine** does not correspond to any known approved or investigational drug as of June 2025; it may be a misspelling or an experimental compound with no widely available data. - **Dexamethasone** is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties, commonly used in various inflammatory conditions, certain cancers (including leukemias), and as supportive care during chemotherapy[6][7][8]. The combination of venetoclax plus azacitidine has demonstrated efficacy in AML by targeting both the apoptotic pathway (venetoclax) and epigenetic regulation (azacitidine)[1][3][4]. Dexamethasone may be included for its anti-inflammatory effects or to manage side effects. The role of "cedarbenazine" cannot be described due to lack of information.